AU2020378197A1 - Methods of treatment with myosin modulator - Google Patents

Methods of treatment with myosin modulator Download PDF

Info

Publication number
AU2020378197A1
AU2020378197A1 AU2020378197A AU2020378197A AU2020378197A1 AU 2020378197 A1 AU2020378197 A1 AU 2020378197A1 AU 2020378197 A AU2020378197 A AU 2020378197A AU 2020378197 A AU2020378197 A AU 2020378197A AU 2020378197 A1 AU2020378197 A1 AU 2020378197A1
Authority
AU
Australia
Prior art keywords
subject
mavacamten
dose
probnp
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020378197A
Other languages
English (en)
Inventor
Danielle L. Aubele
Timothy Carlson
Carlos L. DEL RIO
Milind Y. DESAI
Jay M. Edelberg
Liang Fang
Sarah FERNANDES
Marcus Patrick HENZE
Brian Edmund Kane
Joseph Lambing
Kathy L. LAMPL
Wanying Li
Grace Yanfei MA
Robert Mcdowell
Matthew Edwards MEALIFFE
Steve Nissen
Louis Charles SEHL
Amy SEHNERT
Marc J. SEMIGRAN
David Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of AU2020378197A1 publication Critical patent/AU2020378197A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020378197A 2019-11-10 2020-11-10 Methods of treatment with myosin modulator Pending AU2020378197A1 (en)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962933517P 2019-11-10 2019-11-10
US62/933,517 2019-11-10
US201962933970P 2019-11-11 2019-11-11
US62/933,970 2019-11-11
US201962935922P 2019-11-15 2019-11-15
US62/935,922 2019-11-15
US202063001473P 2020-03-29 2020-03-29
US63/001,473 2020-03-29
US202063002302P 2020-03-30 2020-03-30
US63/002,302 2020-03-30
US202063006701P 2020-04-07 2020-04-07
US63/006,701 2020-04-07
US202063022573P 2020-05-10 2020-05-10
US63/022,573 2020-05-10
US202063059143P 2020-07-30 2020-07-30
US63/059,143 2020-07-30
US202063064450P 2020-08-12 2020-08-12
US63/064,450 2020-08-12
PCT/US2020/059893 WO2021092598A1 (en) 2019-11-10 2020-11-10 Methods of treatment with myosin modulator

Publications (1)

Publication Number Publication Date
AU2020378197A1 true AU2020378197A1 (en) 2022-05-26

Family

ID=75849342

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020378197A Pending AU2020378197A1 (en) 2019-11-10 2020-11-10 Methods of treatment with myosin modulator

Country Status (13)

Country Link
US (1) US20230158027A1 (https=)
EP (1) EP4054588A4 (https=)
JP (1) JP7830321B2 (https=)
KR (1) KR20220113387A (https=)
CN (1) CN114945372A (https=)
AU (1) AU2020378197A1 (https=)
BR (1) BR112022008641A2 (https=)
CA (1) CA3157629A1 (https=)
CL (1) CL2022001217A1 (https=)
IL (1) IL292840A (https=)
MX (1) MX2022005465A (https=)
TW (1) TW202134259A (https=)
WO (1) WO2021092598A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3645002T3 (da) 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
HUE069154T2 (hu) * 2020-01-28 2025-02-28 Assia Chem Ind Ltd A mavakamten szilárd állapotú formái és eljárás elõállításukra
MX2023002024A (es) * 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
DK4243825T3 (da) 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
CN115461052B (zh) * 2020-11-25 2023-12-22 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) * 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
PT4370116T (pt) * 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
CA3248508A1 (en) 2022-04-13 2023-10-19 Assia Chemical Industries Ltd. SOLID STATE FORMS OF MAVACAMTEN AND THEIR PREPARATION METHOD
EP4514355A1 (en) * 2022-04-26 2025-03-05 MyoKardia, Inc. Methods of administering myosin inhibitors
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス， インコーポレイテッド １，４－ジヒドロキナゾリノン化合物およびその使用
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
IT202300016653A1 (it) 2023-08-03 2025-02-03 Olon Spa Processo per preparare mavacamten e intermedio di processo.
WO2025046606A1 (en) 2023-08-26 2025-03-06 Micro Labs Limited Granules of mavacamten for oral administration
WO2025096779A2 (en) * 2023-11-01 2025-05-08 Bristol Myers Squibb Company Methods of treatment with a myosin inhibitor using protein levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
EP3399907A4 (en) * 2016-01-04 2019-08-28 Aventusoft, LLC SYSTEM AND METHOD FOR MEASURING HEMODYNAMIC PARAMETERS FROM THE HEADLAPPING SIGNALS
CA3071948A1 (en) * 2017-08-04 2019-02-07 MyoKardia, Inc. Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Also Published As

Publication number Publication date
MX2022005465A (es) 2022-08-08
EP4054588A1 (en) 2022-09-14
CA3157629A1 (en) 2021-05-14
BR112022008641A2 (pt) 2022-09-13
TW202134259A (zh) 2021-09-16
KR20220113387A (ko) 2022-08-12
CL2022001217A1 (es) 2023-01-13
WO2021092598A1 (en) 2021-05-14
US20230158027A1 (en) 2023-05-25
JP2023501453A (ja) 2023-01-18
CN114945372A (zh) 2022-08-26
IL292840A (en) 2022-07-01
JP7830321B2 (ja) 2026-03-16
EP4054588A4 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
US20230158027A1 (en) Methods of treatment with myosin modulator
WO2022047004A1 (en) Methods of treatment with myosin modulator
US20250241903A1 (en) Treatment of systolic dysfunction
EP1009400B1 (en) Combination therapy comprising atorvastatin and an antihypertensive agent
JP7832128B2 (ja) 心房機能不全の治療
TW202030189A (zh) 經四氫哌喃(thp)取代之雙環嘧啶二酮化合物
US12616697B2 (en) Methods of treatment with myosin modulator
EA052373B1 (ru) Способы лечения модулятором миозина
HK40077232A (en) Methods of treatment with myosin modulator
US20250325531A1 (en) Treatment of systolic dysfunction
EA046692B1 (ru) Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона
EA050645B1 (ru) Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона